Related Experiment Video
Updated: Apr 17, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Cost-effectiveness study of pediatric atopic dermatitis in Asia: atopiclair vs. regular emollient (AD-ATOP)
Insights
Atopiclair, a non-steroidal cream, is a cost-effective treatment for childhood atopic dermatitis (AD) compared to regular emollients. It offers significant annual cost savings across high, middle, and low-income Asia-Pacific countries.
Area of Science:
- Dermatology
- Health Economics
- Pediatrics
Background:
- Atopic dermatitis (AD) is a common childhood condition impacting quality of life.
- Current AD management relies on proactive moisturizing treatments.
Purpose of the Study:
- To evaluate the cost-effectiveness of Atopiclair versus regular emollient for pediatric mild-to-moderate AD.
- Study focused on 12 Asia-Pacific countries.
Main Methods:
- A Markov decision model was utilized for cost-effectiveness analysis.
- Data sourced from literature review, expert opinion, fee schedules, and a 2012 survey.
- Analysis adopted a societal perspective.
Main Results:
- Atopiclair demonstrated cost-effectiveness against regular emollient.
- Annual cost savings per patient were USD786 (high-income), USD499 (middle-income), and USD289 (low-income).
- Sensitivity analyses confirmed Atopiclair's cost-effectiveness.
Conclusions:
- Modeling indicates Atopiclair is a cost-effective option for managing pediatric mild-to-moderate AD.
- This finding applies to the studied Asia-Pacific nations.
Background:
Atopic dermatitis (AD) is a highly prevalent, chronic relapsing condition in childhood with significant financial burden and impact on the quality of life of patients and caregivers. Proactive maintenance treatment with moisturizing agents is the mainstay AD therapy.
Objectives:
The aim of this study was to assess the cost-effectiveness of a non-steroidal barrier cream (Atopiclair), compared to regular emollient in pediatric patients with mild-to-moderate AD.
Methods:
A Markov decision model was developed to evaluate the cost-effectiveness of Atopiclair versus regular emollient in 12 Asia-Pacific countries, grouped by income categories based on gross domestic product (GDP) per capita. Data was obtained from structured literature review, expert opinion, fee schedules, and findings from a 2012 survey of 12 Asia-Pacific countries. Analysis was performed a societal perspective.
Results:
In the base case analysis, Atopiclair was cost-effective against regular emollient, with USD786, USD499, and USD289 in cost savings per year for high, middle, and low-income countries, respectively. Sensitivity analyses showed that Atopiclair remained cost-effective versus regular emollient.
Conclusions:
Modelling analysis showed that Atopiclair is a cost-effective treatment compared to regular emollient for mild-to-moderate pediatric AD in the countries included in the study.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Acne Infection

